National Institute of Allergy and Infectious Diseases, National Institutes of Health - Wednesday, November 30, 2005
Media Contact: NIH Press Office, 301-496-5787
Action Makes A Difference The U.S. Department of Health and Human Services has adopted Action Makes a Difference as the theme for this year s World AIDS Day. Today we remember that we all can make a difference in helping to bring an end to the HIV/AIDS pandemic, regardless of our background or expertise. Everyone has
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, October 31, 2005
Media Contact: Kathy Stover, (301) 402-1663, kstover@niaid.nih.gov
Experiments in female monkeys have for the first time shown that when used in combination, vaginal gels known as microbicides can protect against an HIV-like virus. The research, funded largely by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), suggests
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, October 13, 2005
Together with national, regional and local HIV/AIDS groups and my colleagues at the National Institute of Allergy and Infectious Diseases (NIAID), I am proud to participate in the commemoration of the third annual National Latino AIDS Awareness Day. This day is an opportunity to commend all those who have worked to sto
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, October 11, 2005
Media Contact: NIAID News Office, (301) 402-1663, niaidnews@niaid.nih.gov
A novel vaccine targeted to multiple HIV subtypes found worldwide has moved into the second phase of clinical testing, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today. The study investigators plan to enroll a total of 480 participants a
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Aug. 8, 2005
Media Contact: Linda Joy, (301) 402-1663, ljoy@niaid.nih.gov
A survey of U.S. adults has found that a majority believe that HIV vaccines are the best hope for controlling the global AIDS epidemic and are confident such vaccines can be made. But while most of those surveyed felt it personally important to help support HIV vaccine research, a majority expressed reluctance to suppo
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Thursday, August 4, 2005
Media Contact: Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced an agreement with the International Partnership for Microbicides (IPM) to share information and expertise in an effort to develop vaginal microbicides, which are creams, gels or other substances
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Thursday, July 14, 2005
Media Contact: Linda Joy, (301) 402-1663, ljoy@niaid.nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced funding to establish the Center for HIV/AIDS Vaccine Immunology (CHAVI). Barton Haynes, M.D., of Duke University has been selected to lead the CHAVI consortium. The consortium may receive more t
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, June 14, 2005
Media Contact: Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov
A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today. The novel antibiotic, PA-824
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Thursday, May 19, 2005
Media Contact: Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov
For the first time, scientists have shown that humans use an immune defense process common in plants and invertebrates to battle a virus. The new finding that human cells can silence an essential part of HIV s genetic make-up could have important implications for the treatment of people infected with the virus. Led by
National Institute of Allergy and Infectious Diseases, National Institutes of Health - May 18, 2005
May 19, 2005, marks the first annual National Asian and Pacific Islander HIV/AIDS Awareness Day. This commemorative day aims to raise the awareness of Asians and Pacific Islanders in the United States about the devastating impact of HIV/AIDS as well as educating Asian and Pacific Islander communities about the progress
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Tuesday, May 17, 2005
Media Contact: NIAID News Office, (301) 402-1663, niaidnews@nih.gov
Eighth annual observance encourages all Americans to support the work of researchers and clinical trial volunteers who are working to end the AIDS pandemic May 18th is HIV Vaccine Awareness Day, a day for educating American communities about the ongoing search for a preventive HIV vaccine and for recognizing the effort
National Institute of Allergy and Infectious Diseases, National Institutes of Health - May 12, 2005
May 18, 2005 marks the eighth annual HIV Vaccine Awareness Day. It is a day to educate our communities about the efforts to find a preventive HIV vaccine and to recognize and thank the thousands of volunteers, health professionals and scientists who are conducting and participating in HIV vaccine research. The theme fo
U.S. National Institute for Allergy and Infectious Diseases - February, 2005
Two pre-application meetings will be held in the United States for representatives of institutions that would like to learn more about the Request for Applications (RFA) to establish Clinical Trials Units (CTUs)as part of the HIV/AIDS Clinical Trials Networks of the U.S. National Institutes of Health s Division of AIDS
National Institute of Allergy and Infectious Diseases, National Institutes of Health - February 15, 2005
Media Contact: NIAID News Office, (301) 402-1663, niaidnews@niaid.nih.gov
The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is soliciting applications from U.S. and overseas research institutions seeking to become Clinical Trials Units (CTUs) in the Institute s revamped HIV/AIDS Clinical Trials Networks. NIAID, part of the U.S. National Institutes of H
National Institute of Allergy and Infectious Diseases, National Institutes of Health - February 11, 2005
Media Contact: Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov
A large, multisite trial designed to examine the safety and preliminary effectiveness of two candidate topical microbicides to prevent HIV infection has opened to volunteer enrollment. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, r
National Institute of Allergy and Infectious Diseases, National Institutes of Health - February 4, 2005
Today, February 7th, marks the fifth annual observance of National Black HIV/AIDS Awareness and Information Day--part of a critical effort encouraging individuals to get tested, educated and involved in HIV research activities. The National Institute of Allergy and Infectious Diseases (NIAID), a component of the Nation
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Monday, Jan. 24, 2005
Media Contact: NIAID News Office, (301) 402-1663, niaidnews@niaid.nih.gov
A large clinical trial of a novel HIV vaccine has begun enrolling volunteers at sites in North America, South America, the Caribbean and Australia . Organizers are seeking 1,500 participants. The trial is co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Thursday, January 6, 2005
Media Contact: Paul Williams, (301) 402-1663, pwilliams@niaid.nih.gov
People with more copies of a gene that helps to fight HIV are less likely to become infected with the virus or to develop AIDS than those of the same geographical ancestry, such as European Americans, who have fewer copies of the gene, according to a study funded by the National Institute of Allergy and Infectious Dis
This information is designed to support, not replace, the relationship that exists between you and your doctor.